Join
Live feed
·
PRReleasevia Quantisnow
Fate Therapeutics Inc. logo
Neurocrine Biosciences Inc. logo

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

ByQuantisnow·Wall Street's wire, on your screen.
FATE· Fate Therapeutics Inc.NBIX· Neurocrine Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track FATE (Fate Therapeutics Inc.), NBIX (Neurocrine Biosciences Inc.) and more on Quantisnow.